Dextromethorphan/bupropion

Dextromethorphan/bupropion
Combination of
DextromethorphanNMDA receptor antagonist, σ1 receptor agonist, serotonin–norepinephrine reuptake inhibitor
BupropionNorepinephrine–dopamine reuptake inhibitor, CYP2D6 inhibitor
Clinical data
Trade namesAuvelity
Other namesDXM/BUP; AXS-05
License data
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Dextromethorphan/bupropion, sold under the brand name Auvelity, is a combination medication for the treatment of major depressive disorder (MDD) and agitation associated with dementia due to Alzheimer's disease. Its active components are dextromethorphan (DXM) and bupropion. It is taken as a tablet by mouth.

Side effects of dextromethorphan/bupropion include dizziness, headache, diarrhea, somnolence, dry mouth, sexual dysfunction, and hyperhidrosis, among others. The mechanism of action of dextromethorphan/bupropion in the treatment of depression is unknown.

Dextromethorphan/bupropion was developed by Axsome Therapeutics and was approved for the treatment of major depressive disorder in the United States in August 2022.